Total Payments
$249,196
2024 Payments
$26,606
Companies
75
Transactions
682
Medicare Patients
15,704
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$160,640 (64.5%)
Consulting$62,124 (24.9%)
Food & Beverage$16,857 (6.8%)
Travel$9,040 (3.6%)
Education$535.23 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $142,910 | 48 | 57.3% |
| Consulting Fee | $62,124 | 24 | 24.9% |
| Honoraria | $17,730 | 7 | 7.1% |
| Food and Beverage | $16,857 | 536 | 6.8% |
| Travel and Lodging | $9,040 | 53 | 3.6% |
| Education | $535.23 | 14 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $152,176 | 141 | $0 (2024) |
| GENZYME CORPORATION | $37,595 | 40 | $0 (2023) |
| Sirtex Medical Inc | $12,139 | 23 | $0 (2019) |
| Celgene Corporation | $10,586 | 29 | $0 (2024) |
| Deciphera Pharmaceuticals Inc. | $3,933 | 7 | $0 (2022) |
| Seagen Inc. | $3,230 | 4 | $0 (2023) |
| PUMA BIOTECHNOLOGY, INC. | $2,388 | 4 | $0 (2024) |
| Adaptive Biotechnologies Corporation | $2,250 | 2 | $0 (2020) |
| Dova Pharmaceuticals | $2,141 | 4 | $0 (2021) |
| ADC Therapeutics America, Inc. | $2,085 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,606 | 89 | AstraZeneca Pharmaceuticals LP ($24,977) |
| 2023 | $48,741 | 96 | AstraZeneca Pharmaceuticals LP ($46,969) |
| 2022 | $40,684 | 50 | AstraZeneca Pharmaceuticals LP ($31,558) |
| 2021 | $37,243 | 29 | AstraZeneca Pharmaceuticals LP ($28,798) |
| 2020 | $29,475 | 45 | AstraZeneca Pharmaceuticals LP ($19,519) |
| 2019 | $39,350 | 118 | GENZYME CORPORATION ($22,712) |
| 2018 | $15,588 | 121 | GENZYME CORPORATION ($10,582) |
| 2017 | $11,509 | 134 | Sirtex Medical Inc ($9,113) |
All Payment Transactions
682 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Oncology | ||||||
| 12/06/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $124.13 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/05/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $42.23 | General |
| Category: Oncology | ||||||
| 12/04/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Oncology | ||||||
| 12/02/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $25.48 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $23.55 | General |
| Category: Hematology | ||||||
| 11/07/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $23.48 | General |
| 10/17/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $35.75 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/10/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Oncology | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: Oncology | ||||||
| 10/08/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,560.00 | General |
| Category: Oncology | ||||||
| 10/07/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: HEMATOLOGY | ||||||
| 10/03/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 09/27/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $380.91 | General |
| Category: Oncology | ||||||
| 09/27/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $112.36 | General |
| Category: Oncology | ||||||
| 09/27/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $49.53 | General |
| Category: Oncology | ||||||
| 09/27/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Oncology | ||||||
| 09/27/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $11.63 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $25.70 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.86 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: Oncology | ||||||
| 08/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $26.51 | General |
| 08/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 51 | 3,779 | 154,482 | $992,293 | $440,647 |
| 2022 | 54 | 4,341 | 192,910 | $1.2M | $520,834 |
| 2021 | 49 | 4,133 | 199,404 | $1.2M | $553,414 |
| 2020 | 49 | 3,451 | 129,112 | $872,798 | $412,500 |
Total Patients
15,704
Total Services
675,908
Medicare Billing
$1.9M
Procedure Codes
203
All Medicare Procedures & Services
203 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 90 | 138,000 | $276,000 | $120,483 | 43.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 65 | 5,820 | $173,280 | $103,648 | 59.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 169 | 271 | $54,847 | $23,200 | 42.3% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 20 | 67 | $37,511 | $22,223 | 59.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 85 | 170 | $47,672 | $21,379 | 44.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 243 | 319 | $45,097 | $17,070 | 37.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 45 | 188 | $70,935 | $16,930 | 23.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 409 | 1,101 | $19,872 | $11,320 | 57.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 374 | 1,406 | $19,736 | $10,675 | 54.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 425 | 1,245 | $18,636 | $10,431 | 56.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 64 | 64 | $21,888 | $9,809 | 44.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 105 | 192 | $35,520 | $8,069 | 22.7% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 206 | 482 | $11,615 | $6,410 | 55.2% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 15 | 80 | $5,600 | $5,811 | 103.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 108 | $22,909 | $5,295 | 23.1% |
| 83550 | Iron binding capacity | Office | 2023 | 236 | 527 | $7,935 | $4,501 | 56.7% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 64 | 427 | $6,832 | $3,891 | 57.0% |
| 82668 | Erythropoietin (protein) level | Office | 2023 | 96 | 211 | $6,752 | $3,868 | 57.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 35 | 174 | $14,889 | $3,484 | 23.4% |
| 83540 | Iron level | Office | 2023 | 236 | 527 | $5,820 | $3,324 | 57.1% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 31 | 174 | $5,220 | $2,945 | 56.4% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 12 | 60 | $9,600 | $2,361 | 24.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $6,475 | $2,258 | 34.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 99 | 210 | $14,070 | $2,103 | 14.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 17 | 43 | $8,396 | $1,878 | 22.4% |
About Dr. Jack Erter, MD
Dr. Jack Erter, MD is a Hematology & Oncology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1821145624.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jack Erter, MD has received a total of $249,196 in payments from pharmaceutical and medical device companies, with $26,606 received in 2024. These payments were reported across 682 transactions from 75 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($142,910).
As a Medicare-enrolled provider, Erter has provided services to 15,704 Medicare beneficiaries, totaling 675,908 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 203 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Nashville, TN
- Active Since 01/04/2007
- Last Updated 06/05/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1821145624
Products in Payments
- CALQUENCE (Drug) $117,985
- TAGRISSO (Drug) $23,025
- CD38 (Drug) $21,313
- SIR-Spheres Microspheres (Device) $12,139
- JEVTANA (Drug) $11,409
- IMFINZI (Biological) $10,528
- Revlimid (Drug) $8,183
- QINLOCK (Drug) $3,933
- IMBRUVICA (Drug) $3,412
- Nerlynx (Drug) $2,367
- clonoSEQ (Device) $2,250
- Doptelet (Drug) $2,167
- Pomalyst (Drug) $2,104
- TUKYSA (Drug) $1,986
- AYVAKIT (Drug) $1,980
- CINVANTI (Drug) $1,622
- FOTIVDA (Drug) $1,331
- ADCETRIS (Biological) $1,247
- KEYTRUDA (Biological) $847.97
- ELITEK (Drug) $599.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Nashville
Dr. Jonathan Abbas, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Kent Shih, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Alan Tan, M.d, M.D
Hematology & Oncology — Payments: $1.0M
Hematology & Oncology $1.0M
Brian Rini, Md, MD
Hematology & Oncology — Payments: $685,999
Hematology & Oncology $685,999
Jesus Berdeja, M.d, M.D
Hematology & Oncology — Payments: $572,989
Hematology & Oncology $572,989
Dr. Krish Patel, M.d, M.D
Hematology & Oncology — Payments: $568,657
Hematology & Oncology $568,657